The SPCG-7 trial, comparing radiotherapy plus long-term androgen deprivation therapy with life-long androgen deprivation therapy alone in locally advanced prostate cancer (80%) or cT2 with PSA >20 (20%), investigated a similar target group to the SPCG-15 trial, although SPCG-7 was conducted in the pre-MRI era, and results may not be automatically generalizable to all MRI-defined T3 tumors. Here, KLK3 is linked to prostate carcinoma.